TITLE

Fluoroquinolones vs β-Lactams for Empirical Treatment of Immunocompetent Patients With Skin and Soft Tissue Infections: A Meta-analysis of Randomized Controlled Trials

AUTHOR(S)
Falagas, Matthew E.; Matthaiou, Dimitrios K.; Vardakas, Konstantinos Z.
PUB. DATE
December 2006
SOURCE
Mayo Clinic Proceedings;Dec2006, Vol. 81 Issue 12, p1553
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To compare the effectiveness and safety of fluoroquinolones with β-lactams in the treatment of patients with skin and soft tissue infections (SSTIs). METHODS: We searched the PubMed database, Cochrane Database of Controlled Trials, and references of relevant articles for Study reports published between January 1980 and February 2006. RESULTS: Twenty randomized controlled trials that enrolled 4817 patients were included in the analysis. Fluoroquinolones as empirical treatment of patients with SSTIs were more effective than β-lactams for the clinically evaluable patients (90.4% vs 88.2%; odds ratio [0R], 1.29; 95% confidence interval [CI], 1.00-1.66). This was also true in subset analyses of randomized controlled trials that studied ciprofloxacin (OR. 2.49; 95% CI, 1.45-4.26) and for patients with mild to moderate infections (OR, 1.83; 95% Cl, 1.13-2.96). In contrast, no difference was found between the compared regimens for patients with moderate to severe infections (OR, 1.12; 95% Cl, 0.80-1.55), for patients who did not receive third-generation cephalosporins as the comparator antibiotic (OR, 0.99; 95% Cl, 0.73-1.34), or for the microbioiogically evaluable patients (OR, 1.19; 95% Cl, 0.89-1.59). Ruoroquinolones were also associated with more adverse effects (19.2% vs 15.2%; OR, 1.33; 95% CI, 1.13-1.57). CONCLUSION: The high proportion of successfully treated patients in the compared groups of antibiotics and the development of more adverse effects associated with fluoroquinolone use suggest that these antibiotics do not have substantial advantages compared with β-lactams for empirical treatment of patients with SSTIs.
ACCESSION #
24100629

 

Related Articles

  • Tips from Other Journals. Miller, Karl E.; Wellbery, Caroline; Moon, Kenneth T.; Lin, Kenny // American Family Physician;10/1/2007, Vol. 76 Issue 7, p1036 

    The article provides information on several studies on family medicine. One research has found that loneliness was associated with Alzheimer's disease as well as with lower levels of cognitive function. Meanwhile, a meta-analysis of 20 studies has revealed that fluoroquinolones were more...

  • Prevalence of Extended-Spectrum β-Lactamase Mediated Resistance in Neonatal Septicemia. Gangurde, N.; Mane, M.; Pawar, R. // Pravara Medical Review;Dec2011, Vol. 3 Issue 4, p4 

    With the emergence of Extended Spectrum Beta Lactamase (ESBL) producing Gram negative bacilli (GNB) as the predominant pathogen from cases of neonatal septicemia, this study was specially designed to investigate the prevalence of ESBL producing GNB in neonatal septicemia and to compare the...

  • Encuesta multicéntrica nacional sobre el manejo de la infección en pacientes alérgicos a betalactàmicos. Serrano, R.; Capdevila, J. A.; Mensa, J.; Barberán, J. // Revista Española de Quimioterapia;2009, Vol. 22 Issue 1, p10 

    Introduction. Beta-lactam antibiotics are widely prescribed to treat many infections because of efficacy, spectrum and safety. Their use is limited in patients with resistant microbial agents and in those with a history of penicillin allergy (HPA) because of cross-reactivity risk. Accurate...

  • Multiple drug resistance of Aeromonas hydrophila isolates from Chicken samples collected from Mhow and Indore city of Madhyapradesh. Kaskhedikar, M.; Chhabra, D. // Veterinary World;Jan2009, Vol. 2 Issue 1, p31 

    Fourteen antibacterial agents belonging to 9 different groups of antibiotics viz. aminoglycosides, cephalosporins, nitrofurantoin, fluroquinolones, chloramphenicol, sulphonamides, tetracyclines, penicillin and polymixin were used for in vitro sensitivity testing of Aeromonas hydrophila isolated...

  • Multidrug-Resistant Streptococcus pneumoniae Infections:Current and Future Therapeutic Options. Van Bambeke, Françoise; Reinert, René R.; Appelbaum, Peter C.; Tulkens, Paul M.; Peetermans, Willy E. // Drugs;2007, Vol. 67 Issue 16, p2355 

    Antibacterial resistance in Streptococcus pneumoniae is increasing worldwide, affecting principally ß-lactams and macrolides (prevalence ranging between ≈1% and 90% depending on the geographical area). Fluoroquinolone resistance has also started to emerge in countries with high level of...

  • Are all carbapenems the same? Boeser, Kimberly D. // Infectious Disease News;Nov2008, Vol. 21 Issue 11, p12 

    The article offers information on the use and kinds of carbapenems used in clinics in the U.S . According to the article, there are four carbapenems existin in the U.S. market. They are imipenem/cilistatin, meropenem, ertapenem and doripenem, which are four beta lactam antibiotics of the...

  • CLINICAL BRIEFS.  // Dermatology Times;Dec2002, Vol. 23 Issue 12, p10 

    Presents news related to dermatology as of December 2002. Effectiveness of beta-lactam antibiotic ertapenem in treating complicated skin and skin structure Staphylococcus aureus infections; Risks in piercing the upper ear cartilage.

  • Clinical Use of the New Beta--Lactam Antimicrobial Drugs. Brooks, Geo F.; Barriere, Steven L. // Annals of Internal Medicine;Apr83, Vol. 98 Issue 4, p530 

    Discusses the clinical use of beta-lactam antimicrobial drugs. Cost-benefit considerations; Results of clinical microbiology laboratory and susceptibility testing; Guidelines for evaluation and use of the antimicrobial agents.

  • Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally. Drusano, George L.; Ambrose, Paul G.; Bhavnani, Sujata M.; Bertino, Joseph S.; Nafziger, Ann N.; Louie, Arnold // Clinical Infectious Diseases;9/15/2007, Vol. 45 Issue 6, p753 

    Gram-negative organisms have become increasingly resistant to both b-lactam antibiotics and fluoroquinolones. Consequently, aminoglycoside antibiotics have undergone a resurgence in use. Because of the known toxicities of aminoglycoside antibiotics, clinicians have avoided their use, unless no...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics